NCSTN and triple-negative breast carcinoma: Additionally, the specific monoclonal antibodies against NCSTN were evaluated in cellular and pre-clinical assays, which suggested a promising role of targeting NCSTN for the treatment of invasive triple negative breast cancer [10].